%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture non répertoriées par l'AERES
%A Baldini, C.
%A Charton, E.
%A Schultz, Emilien
%A Auroy, L.
%A Italiano, A.
%A Robert, M.
%A Coquan, E.
%A Isambert, N.
%A Moreau, P.
%A Le Gouill, S.
%A Le Tourneau, C.
%A Ghrieb, Z.
%A Kiladjian, J.J.
%A Delord, J.P.
%A Roca, C. Gomez
%A Vey, N.
%A Barlesi, F.
%A Lesimple, T.
%A Penel, N.
%A Soria, J.C.
%A Massard, C.
%A Besle, S.
%T Access to early-phase clinical trials in older patients with cancer in France : the EGALICAN-2 study
%D 2022
%L fdi:010090910
%G ENG
%J ESMO Open
%@ 2059-7029
%K FRANCE
%N 3
%P 100468 [7 ]
%R 10.1016/j.esmoop.2022.100468
%U https://www.documentation.ird.fr/hor/fdi:010090910
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2024-07/010090910.pdf
%V 7
%W Horizon (IRD)
%X Background : Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases with age, new drugs should also be evaluated in older patients to assess their safety and efficacy. The EGALICAN-2 study was primarily designed to identify social and/or regional inequalities regarding access to ECT.  We focused on the factors of inequalities in access to ECT in older patients. Patients and methods : During a 1-year period (2015-2016), a survey was conducted in 11 early-phase units certified by the French National Cancer Institute. Results : A total of 1319 patients were included in the analyses: 1086 patients (82.3%) were <70 years and 233 patients (17.7%) were >70 years. The most common tumor types at referral in older patients were gastrointestinal (19.3%), hematological (19.3%), and thoracic tumors (18.0%). Most patients referred to the phase I unit had signed informed consent and the rate was similar across age (92.7% in younger patients versus 90.6% in older patients; P = 0.266). The rate of screening failure was also similar across age (28.5% in younger patients versus 24.3% in older patients; P = 0.219). Finally, in older patients, univariate analyses showed that initial care received in the hospital having a phase I unit was statistically associated with first study drug administration (odds ratio 0.49, 90% confidence interval 0.27-0.88; P = 0.045). Conclusions : Older patients are underrepresented in early clinical trials with 17.7% of patients aged ?70 years compared with the number of new cases of cancer in France (50%). However, when invited to participate, older patients were prone to sign informed consent.
%$ 050MEDECI ; 050EPID